Dr. Refaeli is an expert in the genetic manipulation of cells, regulation of gene expression and transformation in hematopoetic lineages. His research interests focus on three broad area: 1) the contribution of antigen receptor signaling to lymphoid neoplasica; 2) the role of role of proto-oncogenes in the regulation of lymphoid tolerance and disease; and 3) the role of MYC in the regulation of stem cell proliferation, survival, self-renewal and differentiation. Dr. Refaeli is Associate Professor, Charles C. Gates Program in Regenerative Medicine and Stem Cell Biology, Department of Dermatology, University of Colorado Denver School of Medicine. He received his Ph.D. from Harvard University and his A.B. degree from the University of Pennsylvania.
Dr. Turner has extensive experience in the areas of molecular biology and genetics, biochemistry and the genetic manipulation of viruses and various hematopoietic cell types, including stem cells, mature lymphoid and myeloid cells. In addition to his role at Taiga, Dr. Turner is Research Instructor, Charles C. Gates Program in Regenerative Medicine and Stem Cell Biology, Department of Dermatology, University of Colorado Denver School of Medicine. He received his Ph.D. from the University of Colorado Health Sciences Center, holds a Masters in Public Health from the Johns Hopkins School of Public Health and received his A.B. degree from Cornell University.
Dr. Bird is coordinating the basic science and genetic engineering of the blood stem cells used to generate human antibodies. Prior to joining Taiga Biotechnologies, Dr. Bird spent eight years as a scientist at biotechnology companies Cytokine Sciences and Sangamo BioSciences. He received his Ph.D. from the University of Colorado Health Sciences Center and his B.A. from the University of Colorado, Boulder.
